Wikipedia -WSS

Wikipedia

author：focus 2025-08-28 08:39:47 - browse：769

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： New England Journal of Medicine addresses racist history, slavery

entertainment

WSS

The SUPPORT Act is critical to fighting the opioid crisis

Chronically ill young patients struggle to find fertility info

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Federal weight loss drug coverage is 30 years out of date

Videos point to link between seizures and unexplained toddler deaths

focus

Wikipedia

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Why psychiatrists like me stop taking insurance

Medicare details structure of new drug price negotiation program

HHS names first

BioMarin wins approval for gene therapy to treat hemophilia A

New England Journal of Medicine addresses racist history, slavery

After affirmative action ruling, medical educators look to 'holistic review'

How a scoliosis diagnosis changed the life of one young dancer

Medical records are filled with copy

Fauci’s Covid grilling leads GOP to weigh foreign research rules

leisure time

Risky weight loss products often used by teens globally, per study

Feng Zhang CRISPR delivery startup lays off quarter of staff

New England Journal of Medicine addresses racist history, slavery

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Fauci’s Covid grilling leads GOP to weigh foreign research rules

The FDA must approve intranasal treatments for anaphylaxis

hotspot

focus

entertainment

hotspot